The wealth of information connecting circadian disruption and metabolic syndrome has prompted an interest in the development of pharmacological clock-targeting compounds aiming at attenuating disease symptoms by resetting dysregulated circadian rhythms (184) whereas a wide range of small molecules are currently explored as likely pharmacologic leads (185, 186). The gene discussed is CLOCK; the disease is metabolic syndrome.